Deca-Durabolin

Contents

Nandrolone decanoate.

Action

Deca-Durabolin is an injectable anabolic preparation. The decanoate ester gives the preparation a duration of action of about 3 weeks after injection.
Nandrolone is chemically related to the male hormone. Compared to testosterone, it has an enhanced anabolic and a reduced androgenic activity. This has been demonstrated in animal bioassays and explained by receptor-binding studies. The low androgenicity of nandrolone is confirmed in clinical use.
In humans, Deca-Durabolin has been shown to positively influence calcium metabolism and to increase bone mass in osteoporosis. In women with disseminated mammary carcinoma, Deca-Durabolin has been reported to produce objective regressions for many months. Furthermore, Deca-Durabolin has nitrogen-saving action. This effect on protein metabolism has been established by metabolic studies and is utilized therapeutically in conditions where a protein deficiency exists eg, during chronic debilitating diseases and after major surgery and severe trauma. In these conditions, Deca-Durabolin serves as a supportive adjunct to specific therapies and dietary measures as well as parenteral nutrition.
Androgenic effects (eg, virilisation) are relatively uncommon at the recommended dosages. Nandrolone lacks the C-17α-alkyl group which is associated with the occurrence of liver dysfunction and cholestasis.

Action

Indications/Uses

As an adjunct to specific therapies and dietary measures in pathologic conditions characterised by a negative nitrogen balance. Osteoporosis. Palliative treatment of selected cases of disseminated mammary carcinoma in women.

Overdosage

The acute toxicity of nandrolone decanoate in animals is very low. There are no reports of acute overdosage with Deca-Durabolin in humans.

Contraindications

Known or suspected prostatic carcinoma or mammary carcinoma in the male.

Special Precautions

Special Precautions

If signs of virilisation develop, discontinuation of the treatment should be considered, preferably in consultation with the patient.
It is recommended to monitor patients with any of the following conditions: Latent or overt cardiac failure, renal and hepatic dysfunction, hypertension, epilepsy, diabetes or migraine (or a history of these conditions), since anabolic steroids may occasionally induce fluid retention; incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure; skeletal metastases of breast carcinoma. In these patients, hypercalcaemia may develop both spontaneously and as a result of anabolic steroid therapy. The latter can be indicative of a positive tumour response to the hormonal treatment. Nevertheless, the hypercalcaemia should first be treated appropriately and after restoration of normal calcium levels, hormone therapy can be resumed; liver dysfunction.
The use of anabolic steroids to enhance athletic ability may carry severe risks to the user’s health and should be discouraged.

Adverse Reactions

High dosages, prolonged treatment and/or too frequent administration may cause virilisation which appears in sensitive women as hoarseness, acne, hirsutism and increase of libido; in prepubertal boys, as an increased frequency of erections and phallic enlargement, and in girls, as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice.
Amenorrhoea and inhibition of spermatogenesis. Premature epiphyseal closure.
Fluid retention.